[Immunotherapy for Bladder Cancer].

Area of Science:

• Oncology
• Immunology
• Uro-oncology

Background:

• Urothelial carcinoma, the most common urological malignancy, has limited treatment options for metastatic or cisplatin-refractory disease.
• Traditional treatments include Bacillus Calmette-Guerin for superficial bladder cancer and cisplatin-based chemotherapy for metastatic disease.
• Tumor microenvironment studies highlight the immune system's role, with CD8 lymphocyte infiltration correlating with better survival.

Purpose of the Study:

• To review the role of PD-1/PD-L1 inhibitors in urothelial carcinoma treatment.
• To discuss the efficacy and tolerability of these novel immunotherapies.
• To outline the current regulatory status of PD-1/PD-L1 inhibitors in the US and Europe.

Main Methods:

• Review of clinical studies and trial data on PD-1/PD-L1 inhibitors in urothelial carcinoma.
• Analysis of tumor microenvironment factors, including PD-L1 expression and CD8 lymphocyte infiltration.
• Assessment of treatment response, survival data, and toxicity profiles.

Main Results:

• PD-1/PD-L1 inhibitors demonstrate a correlation between PD-L1 expression and treatment response in urothelial tumors.
• Several PD-1/PD-L1 inhibitors (atezolizumab, nivolumab, pembrolizumab, durvalumab, avelumab) are approved or in advanced trials, primarily as second-line treatments.
• These agents are generally well-tolerated, with common toxicities including fatigue, lymphopenia, and anemia.

Conclusions:

• PD-1/PD-L1 inhibitors represent a significant advancement in urothelial carcinoma treatment, particularly for platinum-refractory patients.
• These immunotherapies offer a valuable alternative for patients with contraindications or intolerance to traditional chemotherapy regimens.
• Ongoing research and clinical trials continue to expand the role of immunotherapy in bladder cancer management.